• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    High Drug Loading Amorphous Solid Dispersions

    Parenteral Drug Delivery Trends

    Selecting the Right Outsourcing Model for Emerging Biotech

    Inhaled Drug Delivery Technology

    The Future of Biologics: Accelerating Production, Reducing Costs
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Spark Therapeutics Appoints CTO

    Cryoport Launches ESG Program

    U.S. Govt. Purchases 100k Doses of Lilly's COVID-19 Antibody Cocktail

    Thermo Fisher Scientific Completes Mesa Biotech Acquisition

    Ashfield Engage, Popit Form Digital Monitoring Collaboration
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Solid Dose Market Trends

    CatSci Opens New Site in UK

    Pfizer Partners with Medicines Manufacturing Innovation Center

    C2 Pharma Completes Multiple Regulatory Filings

    Bormioli Opens New Glass Research Center
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Covectra Introduces Next-Gen Serialization Solution

    Bormioli Opens New Glass Research Center

    Centrient Pharmaceuticals to Acquire Astral SteriTech

    Seasonal Vaccine Manufacturing

    PwC Joins Medicines Manufacturing Innovation Centre
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Ashfield Engage, Popit Form Digital Monitoring Collaboration

    AMRI Contributes to Efforts to Increase COVID-19 Vax Supply

    CatSci Opens New Site in UK

    Pfizer Partners with Medicines Manufacturing Innovation Center

    CrownBio & JSR Life Sciences Partner with Cambridge Quantum Computing
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

    Top BioPharma Form Accumulus Synergy

    Global Biosciences Co. Selects ValGenesis VLMS

    Gene Therapy Co. Selects ValGenesis' SaaS Platform

    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Adare Pharma Solutions

    Emergent BioSolutions

    Reed-Lane

    Baxter BioPharma Solutions

    Alcami
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Alcami

    test company saurabh

    Almac Group

    Emergent BioSolutions

    Baxter BioPharma Solutions
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Features

    Not Your Father’s Oral Thin Film

    A look at how oral film drug delivery is evolving.

    Not Your Father’s Oral Thin Film
    The overall oral thin film drug delivery market is expected to grow to approximately $2.1 billion by 2025 from about $1.2 billion in 2015.
    Related CONTENT
    • Ashfield Engage, Popit Form Digital Monitoring Collaboration
    • Solid Dose Market Trends
    • Manufacturing Equipment Trends
    • Pfizer Partners with Medicines Manufacturing Innovation Center
    • ACG Launches ACG Laboratories
    Rodolphe Obeid, Vice President of Operations, IntelGenx06.04.20
    Nearly fifty years after oral films offered Americans the promise of minty fresh breath on the go, they continue to attract attention. Thin oral films have since delivered drugs for treating opioid addiction, amyotrophic lateral sclerosis (ALS), and schizophrenia, among other diseases - and many more are in development for chronic conditions such as migraines and neurological diseases such as Alzheimer's.

    But innovations in drug development are happening at a rapid clip. Drug developers and manufacturers are moving beyond traditional small molecule drugs to biologics, personalized therapies promise new ways of attacking cancer, and the aging population is driving demand for better, more convenient medications. Will oral thin films evolve, too?

    The overall oral thin film drug delivery market is expected to grow to approximately $2.1 billion by 2025 from about $1.2 billion in 2015, driven in large part by new products and technological advances in the manufacturing process for oral thin films, according to Roots Analysis Market Research. Demand is rising globally, and the market is growing particularly rapidly in North America, where there is an unmet need and a higher adoption rate. The U.S. Food and Drug Administration has approved approximately 11 oral film products, and more are in development.

    Early versions of the technology were brought to market to offer elderly or pediatric patients with swallowing difficulties an alternative to tablets and capsules, an advantage that stands today. It's estimated that approximately 15 million Americans suffer from difficulty swallowing, or dysphagia, with half of Americans over 60 experiencing some form of dysphagia in their lifetime. Despite their potential, early oral thin films were initially limited by their smaller dosages, reduced stability and potency.

    Thin oral films are easily placed on or under the tongue or against the cheek. Upon contact with saliva or buccal mucosa, the active pharmaceutical ingredient (API) is rapidly released and absorbed systemically or simply swallowed. Oral thin films deliver precise and flexible dosages as well. These attributes make oral films not only easy and convenient, but also convey medical benefits. With buccal or sublingual film delivery, drugs are absorbed quickly in the mouth. This limits gastrointestinal tract exposure and overcomes common challenges associated with tablets and capsules, such as first-pass metabolism, gastrointestinal side effects, and slow or limited absorption in the gastrointestinal tract. As a result, buccal or sublingual films may offer better bioavailability, reduced side effects and improved patient compliance.

    From a business standpoint, oral thin films also offer companies an easy way to protect their products as they go off-patent, extending the revenue life of the drug. Novel oral film applications of reformulated drugs can garner an extra three years of market exclusivity from the FDA or even seven years if the indication is for orphan drugs, as well as patent protection for up to 20 years. 
    While thin oral films have long been recognized for their potential to offer a more efficacious and convenient way to deliver drugs, recent advances in technology and manufacturing make novel applications—think vaccines and high-potency drugs—potential game-changers for drug delivery.

    Unlike early versions of oral thin films, today's oral films can integrate most APIs, including those that are water-soluble and insoluble. They can also be formulated for extended-release. Advances in taste-masking technologies that enhance taste by adding flavors or sweeteners, or that encapsulate the drug to bypass the taste buds to reduce bitterness have made oral thin film drug delivery more palatable as well. Multiple combinations can also be developed, primarily using two APIs in the same film with different absorption profiles. There is also potential for topical use.

    Still, oral thin films have their limitations. Because of the size of oral thin films, the drug load they can carry is limited to a relatively small amount. The larger surface area compared with tablets and capsules also makes them more sensitive to humidity and temperature, which means they must have special packaging for the products to be stable and safe. Dosage uniformity can also be a challenge. Those unstable at a buccal pH or that irritate the mouth are not ideally suited to oral film delivery. Co-administration of multiple drugs is also challenging because of the dissolution time. Lastly, as the drug dissolves in the mouth, taste remains a factor that needs to be addressed for each formula.

    Manufacturing advances
    Oral thin films are composed of single or multiple polymer-based layers, with the intended dose of API controlled by the size and thickness of the film's construction. Typically, oral thin films are about the size of a postage stamp, and the API is either dissolved or held in the polymer matrix of the film. Polymers are chosen to create the viscous bulk material that suspend homogeneously the undissolved ingredients and for how quickly they may dissolve or for the desired physical characteristics of the film. Typical polymers include polyethylene oxide, gelatin, hydroxpropyl methylcellulose, methylcellulose, carboxymethyl-cellulose, polyvinyl pyrrolidone, pectin and pullulan. Plasticizers are also added to the film to make them more robust or more flexible.

    Manufacturing oral films is a relatively quick and straightforward process compared with tablets and capsules, and because of the technology employed can be done continuously. However, the process requires a significant amount of knowledge and expertise to consistently generate a good product, with homogeneity of the API, chemical and physical stability, appealing taste and desired pharmacokinetic profile. The two most widely used processes for making oral thin films are solvent casting and hot metal extrusion, though there are others.

    Solvent casting involves either suspending or dissolving the API in a solvent media, such as organic or aqueous-based solvent, polymers, plasticizers and other ingredients. This bulk material is then cast into a thin layer on a release liner and sent into a heat source such as an oven or convection chamber to be dried. When the film is dry, it is then cut into strips and individually packaged. This process is well suited to heat-sensitive APIs because it's performed at a lower temperature compared with hot metal extrusion. Potential disadvantages of this method include residual solvents on the final product that could pose compliance challenges as well as the need to mitigate possible environmental hazards if the solvents are flammable.

    The hot metal extrusion process heats and combines the dry ingredients with an extruder screw until they melted and thoroughly mixed. The melted material then goes through a flat extrusion die that presses and shapes the film. Elongation rollers may be used to vary the thickness and strength of the film before it is cooled, cut, and packaged. Because of the high temperatures used in this process, there's a risk of degradation. Additionally, any water contained in the ingredients could negatively impact the film's uniformity and strength because of gaps created during the heating process.
    One limitation with manufacturing is the length of time it takes to dry oral thin films. Since elevated temperatures cannot be used with many of the drugs, the films must be air dried at low temperatures over the course of a day, reducing production time.

    In the future, 3D printing could make oral film manufacturing even easier and allow for more customized products but could also take a significant amount of time to produce. Over the past several years, 3D printing has gained interest across multiple industries, and many manufacturers are giving the technology serious consideration.

    While inkjet printing technologies may be too cost-prohibitive, flexographic printing offers an alternative. This technique applies a Fountain roller that transfers ink containing the API in a solution or suspension that transfers the ink to another roller, the Anilox roller. This roller accurately measures the amount of ink required for uniform thickness to the plate cylinder, which holds the polymeric strip. Pressure is applied to print the ink onto the polymer. The advantage of this process is that the film is already manufactured and dried before printing. Therefore, there is a reduced risk of lower API activity due to heat. Production efficiency is also high at an average of 530 films per minute. The drawback to this process is the potential risk of contamination and the requirement for a large print roller.

    Future applications and markets
    While still not in widespread use, oral thin films that incorporate poorly water-soluble drugs could gain more traction as new techniques and strategies for improving solubility are developed. More manufacturers are using organic solvents, and adding solubility enhancers and organic acids to improve solubility. Nanoparticles are being used as carriers for poorly water-soluble drugs and APIs are being micronized to reduce particle size. Other alternatives, such as solid solution, are also an option to increase the solubility of the drug.

    The growth in biopharmaceuticals in general and personalized therapies, more specifically, is also driving innovations in oral film drug delivery. Multilayer film designs could allow for controlled delivery of APIs, and advancements in materials and formulations may pave the way for the more convenient delivery of higher weight molecular drugs than are administered today by oral film.

    As the oral film market moves beyond its traditional focus on small molecules to deliver biologics, vaccines also hold potential for delivery via oral film. Emerging vaccines in development based on DNA, liposomes, particulates, and virus-like particles could be optimized for oral thin films. The buccal mucosa, which contains many immune cells, may be particularly well suited to this type of vaccine delivery. When the oral film comes in contact with saliva, the drug dosage quickly dissolves into the buccal mucosa to deliver the vaccine and elicit an immune response. With buccal administration, there is no first-pass effect, so only a small quantity of vaccine is needed, and the bioavailability is increased. It is also an easy, convenient, and potentially cost-effective method of administration.

    One challenge to vaccine delivery via oral film is the potential for antigen degradation in the saliva. Devising the right particulate formulation to avoid degradation could expand the opportunities for vaccine delivery via oral film. An oral film could also be developed in multiple layers to protect the vaccine from degradation and could be developed in nano or microparticulate form to address these challenges. Buccal and sublingual administration also allow for both systemic and local activity.

    Conventional vaccines may also be administered by oral film. There are several vaccines in film dosage forms being developed today, including those for measles, bacterial typhoid, and rotavirus. Potential to avoid the cold chain is also an attractive path for vaccines in film formulation. Oral film vaccine formulation could also overcome some of the most vexing challenges of conventional vaccines, mainly the difficulty in maintaining a consistent temperature from production to administration. The World Health Organization estimates that more than half of vaccines developed are wasted each year globally due to temperature control and supply chain-related issues. 

    Oral films are also becoming an attractive delivery vehicle for cannabis and other controlled substances, due to their discrete nature, potential fast onset of activity and abuse-resistant features. Companion animals could also represent an opportunity for expansion of oral films, notably because administering medication to companion animals is well recognized as inconvenient and a challenge to compliance.

    As the market for oral thin films grows, it's becoming increasingly important to be able to test and evaluate their effectiveness in a consistent and standard way. To date, the U.S. Pharmacopeia has not released any standard methods for evaluating the essential properties of oral thin films, such as adhesiveness, disintegration or dissolution. In contrast, tablets and capsules have well-defined standards that make it easier to evaluate their effectiveness and manufacturability. Evaluating dissolution is particularly challenging for oral thin films because of the difficulty of reproducing the environment of the oral cavity in vitro.

    Innovations in technology and science have enabled oral thin films to extend far beyond over-the-counter products to deliver drugs to treat a broad spectrum of diseases and conditions. As the population ages and drug development shifts to more personalized treatments, oral films continue to evolve and will play an even more significant role in drug delivery. 


    Rodolphe Obeid, M.Eng., Ph.D, is vice president of operations at IntelGenx Corp. He oversees all operational activities, including manufacturing, packaging, facilities and maintenance, production planning and supply chain management. In addition, he manages process development and manufacturing scale-up of all internal and external pharmaceutical film projects. Dr. Obeid holds a Ph.D. in polymer chemistry from the University of Montreal, Canada and two Masters in polymer science and chemical engineering from the University of Strasbourg, France. He is the co-inventor of several issued and pending patents, and has published numerous scientific articles in recognized international journals and conferences.
    Related Searches
    • Drug Delivery
    Suggested For You
    Ashfield Engage, Popit Form Digital Monitoring Collaboration Ashfield Engage, Popit Form Digital Monitoring Collaboration
    Solid Dose Market Trends Solid Dose Market Trends
    Manufacturing Equipment Trends Manufacturing Equipment Trends
    Pfizer Partners with Medicines Manufacturing Innovation Center Pfizer Partners with Medicines Manufacturing Innovation Center
    ACG Launches ACG Laboratories ACG Launches ACG Laboratories
    Glatt and Aprecia Enter 3D-Printing Collaboration Glatt and Aprecia Enter 3D-Printing Collaboration
    RedHill and Cosmo Strengthen Manufacturing Agreements RedHill and Cosmo Strengthen Manufacturing Agreements
    CDMO Recro Strengthens Leadership Team CDMO Recro Strengthens Leadership Team
    Vaxart Oral COVID-19 Vax Tablet Shows Promise Vaxart Oral COVID-19 Vax Tablet Shows Promise
    BioMed X, Janssen Enter Oral Drug Delivery Alliance BioMed X, Janssen Enter Oral Drug Delivery Alliance
    Pfizer, BioNTech Enter Vax Pact with COVAX  Pfizer, BioNTech Enter Vax Pact with COVAX
    FDA Approves Janssen’s CABENUVA  FDA Approves Janssen’s CABENUVA
    Catalent Acquires Acorda’s INBRIJA Manufacturing Operations Catalent Acquires Acorda’s INBRIJA Manufacturing Operations
    iosBio Inks Exclusive Vax Platform Pact for COVID-19 iosBio Inks Exclusive Vax Platform Pact for COVID-19
    Formulation Development Formulation Development

    Related Features

    • Drug Delivery
      Inhaled Drug Delivery Technology

      Inhaled Drug Delivery Technology

      The success of any new inhaled medicine relies in a large part on the correct combination of formulation and device technology being chosen for its delivery.
      Dr. Sandy Munro, Vice President – Pharmaceutical Development, Vectura 01.27.21

    • Drug Delivery | Injectables
      Self-Medication: Flexibility for Patients and Drug Manufacturers

      Self-Medication: Flexibility for Patients and Drug Manufacturers

      Bringing together self-medication with auto-injectors and sustainable secondary packaging.
      Matthias Heinrichs, Head of Product Management and Project Engineering, Syntegon Technology 11.17.20

    • Drug Delivery
      Wet Wipes Increased Prevalence in Drug Development

      Wet Wipes Increased Prevalence in Drug Development

      A number of factors including patient preference are driving the growth of wet wipes in pharma.
      John Waddell, Business Development Director – Pharma, PDI Contract Manufacturing 10.14.20


    • Drug Delivery | Regulatory Affairs
      Regulatory Overhaul for Medical Devices

      Regulatory Overhaul for Medical Devices

      Implications for the pharmaceutical industry.
      Elizma Parry, Director, Global Clinical Practice, Maetrics 06.04.20

    • Drug Delivery
      CEO Spotlight: Will Downie

      CEO Spotlight: Will Downie

      Vectura’s chief executive talks trends in the inhaled-drug market, and the company’s transition into a CDMO
      Tim Wright, Editor, Contract Pharma 04.01.20

    • Biologics, Proteins, Vaccines | Drug Delivery | Drug Development
      Knowledge Sharing: Biologics Development and Delivery

      Knowledge Sharing: Biologics Development and Delivery

      The increasing importance of sharing information to build awareness and better manage the complexities of drug development.
      Fran L. DeGrazio, Vice President of Scientific Affairs and Technical Services, West Pharmaceutical Services 09.16.19


    • Drug Delivery
      Nasal Drug Delivery

      Nasal Drug Delivery

      A look at best practices for testing nasal drug delivery devices
      Maria Smith, senior manager & Charles Shaw, scientific advisor, Renaissance Lakewood LLC 01.25.19

    • Drug Delivery | Drug Development
      Traveling Toward the Intersection of Drug Development and Delivery

      Traveling Toward the Intersection of Drug Development and Delivery

      Overcoming the challenges of delivering drugs to patients.
      Louise Righton, Global Marketing Operations Manager, 3M Drug Delivery Systems 06.12.18

    • Drug Delivery | Solid Dosage/Creams/Ointments
      FDCs on the Rise

      FDCs on the Rise

      Fixed-dose combination drugs continue to gain traction due to a multitude of benefits they offer, including speed to market a
      Betsy Louda, Associate Editor, Contract Pharma 03.09.18


    • Drug Delivery
      The Future of Inhaled Medications and Inhalation Technology

      The Future of Inhaled Medications and Inhalation Technology

      Formulations, devices and strategy through non-clinical development
      Simon Moore, Envigo 10.11.17

    • Drug Delivery
      Digital Drug Delivery: A Snapshot in Time

      Digital Drug Delivery: A Snapshot in Time

      Technology is transforming the future of drug delivery
      Sam Van Alstyne, 3M Drug Delivery Systems 10.11.17

    • Drug Delivery | Drug Development
      Two Strikes, Two Outs, or Time Out? Inhalation for Systemic Effect

      Two Strikes, Two Outs, or Time Out? Inhalation for Systemic Effect

      The challenges of using the lung as a portal for the treatment of systemic conditions
      Tugrul Kararli, Kurt Sedo, Josef Bossart, PHARMACIRCLE 10.11.16


    • Aseptic Processing | Biosimilars | Drug Delivery | Logistics | Supply Chain
      Improving Packaging Processes to Meet Regulatory and Patient Needs

      Improving Packaging Processes to Meet Regulatory and Patient Needs

      The rise of advanced automation and packaging technologies
      06.02.16

    • Biosimilars | Drug Delivery | Injectables | Parenterals | Serialization | Supply Chain | Vials
      Contract Packaging Market Trends

      Contract Packaging Market Trends

      Contract packagers talk about hot growth areas and the looming 2017 DSCSA deadline
      Tim Wright, Editor 06.02.16

    • Drug Delivery | Drug Development | Excipients | Process Development | Process Validation | Risk Management | Validation
      Process Development Trends

      Process Development Trends

      An approach to process development of pMDIs using cold fill and pressure fill technology
      Steve Haswell, 3M Drug Delivery Systems 05.05.16

    Trending
    • Pfizer Selects Seven Bridges To Support RNA Sequencing Data
    • Pfizer Partners With Medicines Manufacturing Innovation Center
    • Catalent Acquires Delphi Genetics
    • Charles River Acquires CDMO Cognate BioServices
    • Spark Therapeutics Appoints CTO
    Breaking News
    • Spark Therapeutics Appoints CTO
    • Cryoport Launches ESG Program
    • U.S. Govt. Purchases 100k Doses of Lilly's COVID-19 Antibody Cocktail
    • Thermo Fisher Scientific Completes Mesa Biotech Acquisition
    • Ashfield Engage, Popit Form Digital Monitoring Collaboration
    View Breaking News >
    CURRENT ISSUE

    January/February 2021

    • High Drug Loading Amorphous Solid Dispersions
    • Parenteral Drug Delivery Trends
    • Selecting the Right Outsourcing Model for Emerging Biotech
    • Inhaled Drug Delivery Technology
    • The Future of Biologics: Accelerating Production, Reducing Costs
    • Business Intelligence For (and From) the Lab
    • Communicating Your Contracting Priorities to Your Drug Company Customers
    • COVID-19 Impact Report
    • The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Preliminary Study Links Markers of Impaired Bone Health to Vegan Diet
    Refined Grains Linked to Heart Attack Risk, Early Death
    Kappa Bioscience Extends Research Partnership For COVID-19 Research
    Coatings World

    Latest Breaking News From Coatings World

    Nippon Paint Marine Wins Korea Export Award
    Universal Display Corporation, PPG Expand Global Production of UniversalPHOLED Materials
    PPG Introduces Premium Iso-free Primer Surfacer, Catalyst
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    January AI Raises $8.8 Million in New Funding
    FDA Clears Ava Fertility Tracking Wearable Device
    First Patient in Europe Treated With Diamondback 360 Coronary Orbital Atherectomy System
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Spark Therapeutics Appoints CTO
    Cryoport Launches ESG Program
    U.S. Govt. Purchases 100k Doses of Lilly's COVID-19 Antibody Cocktail
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    The Top Beauty Products of 2021, According to HelloGiggles
    Estée Lauder Taps Ana de Armas as Global Brand Ambassador
    Sephora Announces Significant Expansion
    Happi

    Latest Breaking News From Happi

    ACI Urges Senate to Approve Regan as EPA Administrator
    Estée Lauder Signs Actress Ana de Armas
    GUM Recalls Oral Spray
    Ink World

    Latest Breaking News From Ink World

    Etiflex Enters New Markets with Nilpeter FA-22 Installation
    Hydrocarbon Solvents Market to Surpass $8.1 Billion by 2030
    Marshall & Bruce Adds Koenig & Bauer Rapida 106 41-Inch Seven-Color Press
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    FTA converts Forum & INFOFLEX to virtual events
    Xeikon launches two new digital label printing presses
    UFlex adds capacity in packaging films
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Texas Medical Technology Partners with My Protect Kit
    Mexico City Single-Use Plastics Ban Leads to Tampon Shortage
    Believe Diapers Launch in U.S.
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    Fusion Robotics Receives FDA Clearance for Spinal Navigation and Robotics System
    Kaia Health Unveils Next-Gen Complete MSK Care Solutions
    First Implantation of CTL Amedica's Minimally Invasive Flex Tower
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Comercial Kywi Improves Customer Service, Front-Store Operations with Zebra Mobile Solution
    Global Printed Circuit Board Market Projected to Reach $69.32 Billion by 2027
    Global Smart Glass Market to Register 6.8% CAGR Between 2021-28: Grand View Research

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login